当前位置: 首页 >> 检索结果
541. A randomized placebo-controlled trial of arthroscopic lavage versus lavage plus intra-articular corticosteroids in the management of symptomatic osteoarthritis of the knee.
作者: M D Smith.;M Wetherall.;T Darby.;A Esterman.;J Slavotinek.;P Roberts-Thomson.;M Coleman.;M J Ahern.
来源: Rheumatology (Oxford). 2003年42卷12期1477-85页
To assess the efficacy of intra-articular steroid injections following arthroscopy and joint lavage in symptomatic OA of the knee.
543. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis.
作者: F Zulian.;G Martini.;D Gobber.;C Agosto.;C Gigante.;F Zacchello.
来源: Rheumatology (Oxford). 2003年42卷10期1254-9页
To compare the efficacy and safety of intra-articular triamcinolone hexacetonide (TH) and triamcinolone acetonide (TA) in children with oligoarticular juvenile idiopathic arthritis (JIA).
544. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
To compare the efficacy and upper gastrointestinal (GI) safety of valdecoxib 20 and 40 mg daily with those of diclofenac 75 mg slow release (SR) twice daily in treating rheumatoid arthritis (RA).
545. Prognostic factors in lateral epicondylitis: a randomized trial with one-year follow-up in 266 new cases treated with minimal occupational intervention or the usual approach in general practice.
To determine whether minimal intervention by occupational specialists involving information about the disorder, encouragement to stay active and instruction in graded self-performed exercises could enhance the prognosis of lateral epicondylitis compared with the treatment usually given in general practice, to quantify workplace factors associated with the prognosis, and to consider treatments given in general practice.
546. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone.
作者: A Marchesoni.;N Battafarano.;M Arreghini.;B Panni.;M Gallazzi.;S Tosi.
来源: Rheumatology (Oxford). 2003年42卷12期1545-9页
To determine whether patients with early rheumatoid arthritis (RA) treated with cyclosporin A (CsA) and methotrexate (MTX) in combination for 12 months show a lower rate of radiographic deterioration than those treated with MTX alone.
547. Immediate effects of adhesive tape on pain and disability in individuals with knee osteoarthritis.
To evaluate the effects of two knee taping techniques, therapeutic tape and neutral tape, on pain and observed disability in symptomatic generalized knee osteoarthritis (OA).
548. Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise.
作者: C M Tench.;J McCarthy.;I McCurdie.;P D White.;D P D'Cruz.
来源: Rheumatology (Oxford). 2003年42卷9期1050-4页
To test the efficacy of a graded aerobic exercise programme in treating fatigue in systemic lupus erythematosus.
549. Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients.
作者: A J Schuerwegh.;J F Van Offel.;W J Stevens.;C H Bridts.;L S De Clerck.
来源: Rheumatology (Oxford). 2003年42卷4期541-8页
It has been shown that T lymphocytes and monocytes/macrophages, producing pro-inflammatory cytokines, play a pivotal role in the pathophysiology of rheumatoid arthritis (RA). In recent placebo-controlled double-blind randomized studies, chimeric (human/mouse) tumour necrosis factor-alpha (TNFalpha) antibodies (cA2) proved to be very effective in improving clinical disease activity and reducing inflammatory parameters in RA.
550. Long-term efficacy of a cognitive behavioural treatment from a randomized controlled trial for patients recently diagnosed with rheumatoid arthritis.
作者: L Sharpe.;T Sensky.;N Timberlake.;B Ryan.;S Allard.
来源: Rheumatology (Oxford). 2003年42卷3期435-41页
This study examined the long-term efficacy of a cognitive behavioural intervention for patients with recent-onset, seropositive rheumatoid arthritis (RA).
551. Clinical and psychological outcome from a randomized controlled trial of patient-initiated direct-access hospital follow-up for rheumatoid arthritis extended to 4 years.
作者: J R Kirwan.;K Mitchell.;S Hewlett.;M Hehir.;J Pollock.;D Memel.;B Bennett.
来源: Rheumatology (Oxford). 2003年42卷3期422-6页
Patients with rheumatoid arthritis (RA) are traditionally seen regularly as out-patients, irrespective of whether it is appropriate or timely to see them. A randomized controlled trial has shown that over 2 yr, seeing patients only when they or their general practitioner (GP) request a review saves time and resources and is more convenient. This study aimed to assess clinical and psychological outcomes when the trial was extended to 4 yr.
552. A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain.
This randomized, double-dummy, double-blind pilot study of acutely exacerbated low back pain was aimed to inform a definitive comparison between Doloteffin, a proprietary extract of Harpagophytum, and rofecoxib, a selective inhibitor of cyclo-oxygenase-2 (COX-2).
553. The development and evaluation of a drug information leaflet for patients with rheumatoid arthritis.
To develop and assess the effectiveness of a drug information leaflet (DIL) for D-penicillamine (DPA) and determine whether additional verbal information provides enhanced benefit.
554. Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.
Keliximab studies have provided evidence of the therapeutic potential of a non-depleting CD4 monoclonal antibody (mAb) in the treatment of rheumatoid arthritis (RA). Clenoliximab, an immunoglobulin G4 derivative of keliximab, has substantially reduced potential to deplete CD4 cells. In initial studies of clenoliximab, we investigated the hypothesis that the decrease in cell surface CD4 is the result of antibody-mediated stripping from the cell surface.
556. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study.
To compare the efficacy and safety of intra-articular injections of two different hyaluronan preparations and placebo in patients with knee osteoarthritis.
557. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial.
作者: E H S Choy.;G S Panayi.;P Emery.;S Madden.;F C Breedveld.;M C Kraan.;J R Kalden.;A Rascu.;J C C Brown.;N Rapson.;J M Johnston.
来源: Rheumatology (Oxford). 2002年41卷10期1142-8页
Results of an earlier open-label pilot study showed that 4162W94 was a relatively non-depleting anti-CD4 monoclonal antibody that induced >80% down-modulation of CD4 molecules from the surface of T lymphocytes. This placebo-controlled repeat-cycle study was conducted in active rheumatoid arthritis (RA) patients to determine the duration of CD4 blockade required to achieve lasting clinical benefit.
558. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.
作者: E H S Choy.;B Hazleman.;M Smith.;K Moss.;L Lisi.;D G I Scott.;J Patel.;M Sopwith.;D A Isenberg.
来源: Rheumatology (Oxford). 2002年41卷10期1133-7页
Biological products that neutralize tumour necrosis factor alpha (TNF-alpha) are beneficial in rheumatoid arthritis (RA). We studied the effects of CDP870, a novel anti-TNF-alpha antibody fragment modified to obtain a prolonged plasma half-life ( approximately 14 days).
559. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.
作者: K Gottesdiener.;T Schnitzer.;C Fisher.;B Bockow.;J Markenson.;A Ko.;L DeTora.;S Curtis.;L Geissler.;B J Gertz.; .
来源: Rheumatology (Oxford). 2002年41卷9期1052-61页
To evaluate the clinical efficacy and tolerability of etoricoxib in the treatment of osteoarthritis (OA) of the knee and define the clinically active dose range for further clinical trials.
560. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen.
作者: W Bensen.;A Weaver.;L Espinoza.;W W Zhao.;W Riley.;B Paperiello.;D P Recker.
来源: Rheumatology (Oxford). 2002年41卷9期1008-16页
To compare the efficacy of the COX-2 specific inhibitor valdecoxib with the conventional NSAID naproxen and placebo in treating rheumatoid arthritis (RA).
|